# A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC.

Source: https://onco.cc/trials/nct06064812/  
OnCo record `nct06064812` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of FWD1802 in advanced solid tumours, run by Forward Pharmaceuticals Co., Ltd., now recruiting.

## Summary

A Phase I/II Study of FWD1802 in Patients With ER+/HER2- Advanced BC. is a phase 1/2 interventional study registered as NCT06064812 by Forward Pharmaceuticals Co., Ltd., with 99 participants planned, started 2023-09-12 and due to reach its primary completion in 2026-03. Interventions recorded: FWD1802.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06064812
- Phase: 1/2
- Setting: A Phase I/II, Open-label Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Anti-tumor Efficacy of FWD1802in Patients With ER+/HER2- Unresectable Locally Advanced or Metastatic Breast Cancer
- Sponsor: Forward Pharmaceuticals Co., Ltd.
- Enrolled: 99

## Sources

- ClinicalTrials.gov NCT06064812: https://clinicaltrials.gov/study/NCT06064812

## Connected records

- cancers: [Metastatic cancer (cancer that has spread)](https://onco.cc/cancers/metastatic-cancer/)
- companies: [Forward Pharmaceuticals](https://onco.cc/companies/forward-pharmaceuticals/)

---
JSON: https://onco.cc/api/v1/entities/nct06064812.json